ESMO-BC 2021 - ESMO Breast Cancer Annual Congress (Virtual Meeting)
May 05 - May 08, 2021 | BerlinGermany
LARVOL is not affiliated with ESMO Breast Cancer Annual Congress (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 45 abstracts linked to Trials
[VIRTUAL] Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase 1 trial
[VIRTUAL] Atezolizumab with carboplatin as immune induction in metastatic lobular breast cancer: first results of the GELATO-trial
[VIRTUAL] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
[VIRTUAL] Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
[VIRTUAL] Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study
[VIRTUAL] ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast
[VIRTUAL] Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial
[VIRTUAL] Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)
[VIRTUAL] Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study
[VIRTUAL] Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
[VIRTUAL] Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests
[VIRTUAL] Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial
[VIRTUAL] Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study
[VIRTUAL] BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC)
[VIRTUAL] Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high risk early breast cancer: monarchE